Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Sponsor: Medical University of South Carolina
Summary
The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.
Official title: Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
175
Start Date
2021-03-29
Completion Date
2026-12-01
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
40 IU Intranasal Oxytocin
40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Placebo
Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
12 weekly sessions of COPE therapy for PTSD and AUD.
Locations (1)
Medical University of South Carolina
Charleston, South Carolina, United States